Description
<![CDATA[
Investigator’s Brochure (IB) Development & Lifecycle Management
The Investigator’s Brochure is a living document that serves as the comprehensive reference guide for clinical investigators, providing all relevant information about your investigational product. A well-crafted IB is essential for investigator training, site selection, and maintaining regulatory compliance throughout clinical development.
Editverse provides complete IB development and lifecycle management services from initial creation through annual updates and triggered amendments, ensuring your IB remains current and compliant at every stage of development.
📋 What is an Investigator’s Brochure?
The IB is a compilation of clinical and nonclinical data relevant to the study of an investigational product in human subjects. It serves critical functions:
- 📚 Investigator Reference – Comprehensive product information for clinical decision-making
- ⚖️ Benefit-Risk Context – Supports informed consent and patient safety
- 📋 Regulatory Requirement – Mandatory document for IND, CTA, and global submissions
- 🔄 Living Document – Continuously updated throughout clinical development
📜 Regulatory Framework
| Guideline | Requirement |
|---|---|
| ICH E6(R2) | Good Clinical Practice – defines IB content and update requirements |
| FDA 21 CFR 312.23 | IND content requirements – IB as essential component |
| EU CTR 536/2014 | Clinical Trial Regulation – IB requirements for EU submissions |
| ICH M4 | CTD Organization – IB placement in Module 5 |
| PMDA Guidelines | Japan-specific IB requirements for CTN submissions |
📊 IB Sections Developed (ICH E6 Structure)
| Section | Content |
|---|---|
| 1. Summary | Brief overview of physical/chemical properties, pharmacology, and clinical information |
| 2. Introduction | Product name, active ingredients, pharmacological class, rationale for development |
| 3. Physical, Chemical, Pharmaceutical | Formulation, structural formula, storage, preparation instructions |
| 4. Nonclinical Studies | Pharmacology, PK/ADME, toxicology (single/repeat dose, genotox, carcinogenicity, reproductive) |
| 5. Effects in Humans | PK/PD, safety, efficacy from completed clinical studies |
| 6. Summary of Data & Guidance | Benefit-risk discussion, guidance for investigators, dose recommendations |
| 7. References | Published literature, study reports, regulatory documents |
| Appendices | Tables, figures, supporting documentation as needed |
📋 Service Options
| Service Type | Description | Timeline |
|---|---|---|
| New IB Development | Complete de novo IB creation from nonclinical and clinical data packages | 6-10 weeks |
| Annual Update | Routine yearly update incorporating new safety/efficacy data | 3-4 weeks |
| Triggered Update | Safety signal, protocol change, or new study data integration | 2-4 weeks |
| IB Amendment | Specific section revisions (e.g., new indication, formulation change) | 1-2 weeks |
| IB Harmonization | Aligning multiple regional IBs into a single global document | 4-6 weeks |
⚙️ Development Workflow (New IB)
| Phase | Activities | Duration |
|---|---|---|
| 1. Initiation | Kick-off meeting, data inventory, template development | Week 1 |
| 2. Data Collection | Gather nonclinical reports, clinical data, CMC information | Week 1-2 |
| 3. Nonclinical Sections | Write pharmacology, PK, toxicology sections | Week 2-4 |
| 4. Clinical Sections | Write effects in humans, safety, efficacy summaries | Week 3-5 |
| 5. Summary & Guidance | Develop overall summary and investigator guidance | Week 5-6 |
| 6. Internal Review | Medical, scientific, QC review | Week 6-7 |
| 7. Sponsor Review | Client review and comment resolution | Week 7-9 |
| 8. Finalization | Final QC, formatting, delivery | Week 9-10 |
🔄 IB Lifecycle Management
The IB requires regular updates throughout clinical development. Editverse offers comprehensive lifecycle management:
| Update Trigger | Action Required |
|---|---|
| Annual Review | Comprehensive review and update at least annually per ICH E6 |
| New Safety Data | Expedited update for significant safety findings |
| New Clinical Study | Integration of completed study results |
| Protocol Amendment | Dose changes, new populations, indication expansion |
| New Nonclinical Data | Carcinogenicity, reproductive toxicology results |
| Formulation Change | New formulation, route, or presentation |
✨ Why Choose Editverse for IB Development
| Feature | Benefit |
|---|---|
| ICH E6 Expertise | Writers experienced in GCP-compliant IB development |
| Scientific Depth | PhD-level writers for nonclinical and clinical sections |
| Global Compliance | Experience with FDA, EMA, PMDA, NMPA requirements |
| Lifecycle Support | Long-term partnership for ongoing IB maintenance |
| Version Control | Robust tracking of changes and update history |
📦 Deliverables
- ✅ Complete Investigator’s Brochure – ICH E6(R2) compliant
- ✅ Summary Tables – Nonclinical and clinical data summaries
- ✅ Version Control Documentation – Change history and amendments log
- ✅ Word and PDF Formats – Submission-ready documents
- ✅ Reference Package – Supporting literature and study reports list
📞 Get Started
Contact us for a customized proposal based on your development stage and data package:
📧 Email: co*****@*******se.com
🌐 Web: editverse.com
Pricing provided in your local currency. Annual retainer options available for lifecycle management.
]]>
